Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director · President and CEO | February 12, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date February 12, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 871,871 |
Ending reported balance
After 2026-02-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-12 · Grant · Acquired 4,800 · Balance 862,826 F1: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026. Row 2 · 2026-02-12 · Grant · Acquired 15,200 · Balance 878,026 F2: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026. Row 3 · 2026-02-12 · Tax withholding · Disposed 6,155 · Balance 871,871 F3: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
F2: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
F3: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2020 Filed Dec 16, 2020 23:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 2,201 | $42.52 | $93,586.52 |
DisclosureSEC source: 0001177648-20-000051 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,488 F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 23:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001177648-20-000051 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020. The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020. F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis. Read SEC document |
| November 20, 2020 Filed Nov 21, 2020 01:21 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 107,800 | $0.00 Strike: $43.57 | $0.00 |
DisclosureSEC source: 0001177648-20-000035 · edgar.xml · derivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,800 Underlying: Common Stock · 107,800 shares Expires 2030-11-20 F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). Read SEC document |
| November 20, 2020 Filed Nov 21, 2020 01:21 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 26,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000035 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,189 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 20, 2020). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. Read SEC document |
| February 12, 2020 Filed Feb 18, 2020 11:03 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 3,122 | $52.76 | $164,716.72 |
DisclosureSEC source: 0001177648-20-000006 · edgar.xml · nonDerivative · entry 3 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,689 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2020 Filed Feb 18, 2020 11:03 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 8,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000006 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,811 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on March 1, 2018 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2020. Read SEC document |
| February 12, 2020 Filed Feb 18, 2020 11:03 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 1,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000006 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,901 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on March 1, 2018 that vested as a result of the achievement of a research and development milestone in calendar 2019 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2020. Read SEC document |
| December 16, 2019 Filed Jan 6, 2020 23:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000002 · edgar.xml · derivative · entry 3 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis. F4 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 15,000 restricted stock units. 7,500 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment. F1 · derivative.expiration_date: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019. The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019. Read SEC document |
| December 16, 2019 Filed Jan 6, 2020 23:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 3,330 | $63.88 | $212,720.40 |
DisclosureSEC source: 0001177648-20-000002 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,416 F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award. Read SEC document |
| December 16, 2019 Filed Jan 6, 2020 23:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001177648-20-000002 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019. The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019. F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 23:45 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $63.35 | $0.00 |
DisclosureSEC source: 0001177648-19-000038 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2029-11-18 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). Read SEC document |
| October 08, 2019 Filed Oct 9, 2019 21:17 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 7,052 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001177648-19-000035 · edgar.xml · derivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,149 Underlying: Common Stock · 7,052 shares Expires 2022-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 08, 2019 Filed Oct 9, 2019 21:17 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 7,052 | $14.18 | $99,997.36 |
DisclosureSEC source: 0001177648-19-000035 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:16 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 20,730 | $88.88 | $1,842,482.40 |
DisclosureSEC source: 0001177648-19-000009 · edgar.xml · nonDerivative · entry 3 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,194 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:16 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-19-000009 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,924 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:16 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 14,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-19-000009 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,924 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019. Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 00:45 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000040 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:57 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 8,498 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0001177648-18-000032 · edgar.xml · derivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,498 shares Expires 2022-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:57 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 8,498 | $11.77 | $99,990.02 |
DisclosureSEC source: 0001177648-18-000032 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 4,125 | $127.12 | $524,379.08 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 5 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,026 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.80 to $127.52, inclusive. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 7,738 | $126.36 | $977,787.61 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 4 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,151 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.79, inclusive. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 7,538 | $125.27 | $944,264.91 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 3 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,889 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $125.79, inclusive. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 12,622 | $124.26 | $1,568,460.21 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,427 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.74, inclusive. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:56 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,977 | $123.81 | $368,567.78 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.02, inclusive. Read SEC document |
| May 17, 2018 Filed May 18, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 10,968 | $105.83 | $1,160,742.34 |
DisclosureSEC source: 0001177648-18-000026 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,026 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.35, inclusive. Read SEC document |
| May 16, 2018 Filed May 18, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 14,032 | $105.82 | $1,484,912.55 |
DisclosureSEC source: 0001177648-18-000026 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,994 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.00, inclusive. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:27 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 11,132 | $76.85 | $855,438.54 |
DisclosureSEC source: 0001177648-18-000005 · edgar.xml · nonDerivative · entry 3 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,026 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:27 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 20,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-18-000005 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,158 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:27 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 8,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-18-000005 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,421 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018. Read SEC document |
| November 17, 2017 Filed Nov 22, 2017 00:56 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001177648-17-000037 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-11-17 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017). Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 20:13 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 13,925 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001177648-17-000024 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,925 Underlying: Common Stock · 13,925 shares Expires 2023-03-20 F1 · balance_after: On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable. The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. This report reflects the additional shares that became exercisable upon achievement of two of the milestones. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:43 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 2,278 | $29.82 | $67,918.57 |
DisclosureSEC source: 0001177648-17-000006 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,821 F2 · shares: Represents the number of shares of common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU award. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:43 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-17-000006 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,099 F1 · shares: Represents shares of common stock issued upon vesting of a performance share unit ("PSU") award granted on February 20, 2015 as a result of the achievement of a clinical development milestone in 2016 and the settlement and issuance of those shares of common stock on Febuary 13, 2017. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 22:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-16-000008 · edgar.xml · derivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into shares of common stock on a one-for-one basis. F3 · derivative.exercise_date: Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. F3 · derivative.expiration_date: Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 22:53 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001177648-16-000008 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2026-11-18 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2016). Read SEC document |
| September 28, 2016 Filed Sep 29, 2016 21:24 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 6,957 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001571211-16-000004 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,957 Underlying: Common Stock · 6,957 shares Expires 2023-03-20 F1 · balance_after: On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable. The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. This report reflects the additional shares that became exercisable upon achievement of one of the milestones. As of the date of this filing, a total of 33.33% of the shares subject to the option have become exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.